The team’s starting point was the observation that osteoarthritis is driven largely by the progressive loss of the extracellular matrix, the network of collagens and proteoglycans that gives cartilage its resilience. When chondrocytes, the resident cells of cartilage, are exposed to inflammatory signals such as interleukin-1 beta, they ramp up enzymes that chew through this matrix, including members of the ADAMTS family. Current clinical options have shown limited efficacy in halting this degradation, which makes the search for the regulatory switches controlling matrix integrity a central goal of osteoarthritis research.

To model the disease in the laboratory, the researchers treated rat chondrocytes with 10 nanograms per milliliter of interleukin-1 beta for 24 hours. This well-established protocol reliably triggers an inflammatory, matrix-degrading phenotype. The team then measured the secretion of the inflammatory cytokines TNF-alpha and IL-6 by enzyme-linked immunosorbent assay, assessed the abundance of matrix components using alcian blue staining, and tracked the expression of candidate molecules with reverse transcription quantitative PCR, western blotting, and immunofluorescence staining. These complementary readouts allowed them to connect molecular changes at the level of genes and proteins to the physical integrity of the matrix the cells maintain.

The first key finding concerned AURKA, a kinase best known for controlling cell division but increasingly implicated in cartilage biology. When chondrocytes were stimulated with interleukin-1 beta, AURKA levels rose while the expression of both DOT1L and ITCH fell. This inverse relationship suggested a regulatory circuit in which ITCH normally restrains AURKA. Follow-up experiments using co-immunoprecipitation confirmed a physical interaction between ITCH and AURKA and demonstrated that ITCH promotes the ubiquitination of AURKA, tagging the kinase for destruction by the cell’s protein degradation machinery. When ITCH was abundant, AURKA was degraded; when ITCH dwindled under inflammatory conditions, AURKA accumulated.

The consequences for the cartilage matrix were striking. The experiments showed that ITCH, by promoting AURKA ubiquitination and degradation, attenuated the interleukin-1 beta-stimulated degradation of the extracellular matrix in rat chondrocytes. In other words, ITCH acts as a protective brake: its activity keeps AURKA levels in check, and low AURKA corresponds to a better-preserved matrix. This finding builds on earlier work by the same group, which had reported that the E3 ligase HECTD1 similarly targets AURKA for ubiquitination, and that inflammation disrupts that process to drive matrix degradation through enhanced translation of ADAMTS12. The new study adds a second E3 ligase, and an upstream epigenetic controller, to this emerging network.

That upstream controller is DOT1L, a histone methyltransferase that deposits the H3K79me3 mark on histone H3 at lysine 79. Unlike many histone modifications, H3K79 methylation occurs within the body of transcribed genes and is associated with active gene expression. Using chromatin immunoprecipitation, or ChIP, the researchers detected enrichment of both DOT1L and the H3K79me3 mark at the promoter region of the ITCH gene, indicating that DOT1L directly boosts ITCH transcription through this epigenetic modification. When DOT1L activity is reduced, as it is under inflammatory stimulation, H3K79me3 at the ITCH promoter drops, ITCH expression falls, AURKA escapes degradation, and matrix-degrading programs gain the upper hand.

To test whether reinforcing this axis could protect cartilage in a living organism, the team established a rat model of osteoarthritis induced by anterior cruciate ligament transection, a surgical model that mimics post-traumatic osteoarthritis in humans. Into the injured joints they injected a lentivirus engineered to drive overexpression of DOT1L. The joints were subsequently analyzed by hematoxylin and eosin staining, safranin O-fast green staining, and immunohistochemistry, standard histological approaches for assessing cartilage structure and proteoglycan content. All animal procedures were reviewed and approved by the Animal Ethics Committee of Hunan Provincial People’s Hospital.

The in vivo results supported the mechanistic model. Overexpression of DOT1L alleviated the cartilage degeneration caused by ligament transection, and molecular analysis revealed the expected downstream signature: the surgery-induced downregulation of ITCH was reversed, while the surgery-induced upregulation of AURKA and the matrix-degrading enzyme ADAMTS5 was blunted. In effect, elevating DOT1L re-engaged the epigenetic-to-proteolytic pathway that injury had silenced, preserving the cartilage that would otherwise have been lost. These findings identify the DOT1L/ITCH/AURKA axis as a key epigenetic and post-translational regulatory mechanism that protects against extracellular matrix degradation in osteoarthritis.

The study also fits into a broader and growing body of evidence that DOT1L is a guardian of cartilage health. Previous work has shown that mice deficient in Dot1l in cartilage are more susceptible to both spontaneous and post-traumatic osteoarthritis, and that hypoxia induces DOT1L in articular cartilage as a protective response. Research on inhibitors of the H3K79 demethylases KDM7A/B has likewise suggested that restoring H3K79 methylation can protect against osteoarthritis. Meanwhile, ITCH has previously been shown to limit post-traumatic osteoarthritis progression in mice by inhibiting macrophage polarization, and to improve lipopolysaccharide-induced chondrocyte injury by mediating ubiquitination of JAG1. The new study ties these threads together into a single coherent pathway, from chromatin marks through E3 ligase activity to kinase stability and matrix integrity.

The translational implications are considerable. If the DOT1L/ITCH/AURKA axis behaves similarly in human cartilage, strategies that boost DOT1L activity or H3K79me3 deposition, stabilize ITCH, or blunt AURKA accumulation in chondrocytes could slow or halt the matrix destruction that defines the disease. Because DOT1L inhibitors already exist and are being tested in oncology, the enzymology of this target is comparatively well understood, although any therapeutic repurposing would require careful evaluation of DOT1L’s roles in other tissues, where it participates in processes ranging from cardiac stress responses to cell proliferation and differentiation. The authors note that their findings collectively illuminate how epigenetic regulation and protein ubiquitination intersect to govern joint health, and the work was supported by the Research Project of Hunan Provincial Health Commission. For millions of people living with osteoarthritis, the study offers something that has been in short supply: a precisely mapped molecular circuit whose restoration in an animal model measurably preserved cartilage, and which now stands as a concrete starting point for designing drugs that attack the disease at its mechanistic roots rather than merely masking its symptoms.

Subject of Research: Epigenetic and post-translational regulation of cartilage extracellular matrix degradation in osteoarthritis via the DOT1L/ITCH/AURKA axis

Article Title: DOT1L-mediated H3K79me3 of ITCH promotes AURKA ubiquitination to suppress ECM degradation in osteoarthritis

Article References: DOT1L-mediated H3K79me3 of ITCH promotes AURKA ubiquitination to suppress ECM degradation in osteoarthritis. (n.d.). https://doi.org/10.1007/s00438-026-02514-z

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02514-z

Keywords: osteoarthritis, DOT1L, H3K79me3, ITCH, AURKA, ubiquitination, extracellular matrix, chondrocytes, epigenetics, cartilage degradation, ADAMTS5, interleukin-1 beta